Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04053322
Title Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF)
Acronym DOLAF
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors UNICANCER
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA

Facility Status City State Zip Country Details
Institut de Cancerologie de Montpellier Montpellier 34000 France Details
Centre Henri-Becquerel Rouen 76000 France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field